"AstraZeneca plans major $3.5bn expansion drive in the US" was originally created and published by Investment Monitor, a ...

The boosted U.S. investment is said to be a response to Donald Trump’s election win, and leaves in doubt the pharmaceutical ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding ...

German business confidence has collapsed, industry data show, as Olaf Scholz announced Germany will hold national elections ...

After hitting record highs following Trump’s victory, the Dow and S&P 500 hit the brakes on Tuesday, a day before the release ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

Before the end of last year, we entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's integrated drug ...